```html

Junctureal Keratitis: A Complete Patient‑Friendly Guide

Overview

Junctureal keratitis (also called junctional epithelial keratitis or limbal‑junction keratitis) is an inflammation of the corneal epithelium that originates at the limbal–conjunctival junction, the area where the transparent cornea meets the vascularized conjunctiva. The condition is most often linked to viral infection—particularly Herpes Simplex Virus (HSV) type 1—but can also be triggered by bacterial, fungal, or allergic processes that disrupt the epithelial barrier at this junction.

Although the exact prevalence is difficult to quantify because many cases are mild and resolve without specialist care, epidemiological studies estimate that HSV‑related keratitis accounts for approximately 0.5–1.5 % of the global population at some point in life, and up to 30 % of these cases involve the limbal or junctional region [1][2]. The disease can affect anyone, but it is most common in:

• Adults aged 20–50 years (peak incidence around 35 years)
• Individuals with a history of cold sores or prior ocular HSV infection
• People with compromised ocular surface immunity (e.g., due to contact‑lens wear, dry eye, or ocular surgery)

Symptoms

Symptoms may appear suddenly or progress over several days. The following list covers the full spectrum of clinical presentations:

Typical ocular symptoms

• Redness – localized to the limbal area, often described as a “cuff” of blood vessels.
• Eye pain or discomfort – ranging from mild irritation to sharp, stabbing pain.
• Foreign‑body sensation – feeling that something is in the eye.
• Tearing (epiphora) – excessive watery discharge.
• Photophobia – increased sensitivity to light.
• Blurred vision – usually mild to moderate; severe loss suggests deeper stromal involvement.
• Decreased visual acuity – may fluctuate throughout the day.
• Sticky or mucous discharge – occasionally seen with secondary bacterial colonisation.

Signs visible to an eye‑care professional

• Fine, punctate epithelial erosions at the limbal junction.
• Characteristic dendritic or branched corneal lesions (more typical of HSV keratitis).
• Subtle stromal haze if the inflammation extends deeper.
• In chronic cases, peripheral neovascularization (new blood vessels growing into the cornea).

Causes and Risk Factors

Primary causes

• Herpes Simplex Virus‑1 (HSV‑1) – the most common trigger; the virus reactivates from the trigeminal ganglion and spreads to the ocular surface.
• Herpes Zoster Virus (HZV) – less common; may cause keratitis after shingles involving the ophthalmic branch of the trigeminal nerve.
• Bacterial pathogens – Staphylococcus aureus, Pseudomonas aeruginosa (especially in contact‑lens wearers).
• Fungal organisms – Candida, Aspergillus (rare, typically in immunocompromised hosts).
• Allergic inflammation – seasonal or perennial allergic conjunctivitis can disrupt the epithelial barrier.

Risk factors that increase susceptibility

• History of recurrent HSV oral or genital lesions.
• Immunosuppression (e.g., HIV infection, organ transplantation, systemic steroids).
• Chronic ocular surface disease: dry eye, meibomian gland dysfunction, blepharitis.
• Contact‑lens wear, especially extended‑wear lenses or poor hygiene.
• Previous ocular surgery (LASIK, cataract extraction) or trauma.
• Systemic conditions that impair healing such as diabetes mellitus.
• High UV‑light exposure – can precipitate viral reactivation.

Diagnosis

Accurate diagnosis relies on a combination of patient history, clinical examination, and targeted laboratory tests.

Clinical examination

• Slit‑lamp biomicroscopy – the gold‑standard tool; allows visualization of dendritic lesions, punctate epithelial erosions, and vascular changes.
<
• Fluorescein staining – highlights epithelial defects; dendritic patterns fluoresce bright white against a dark background.
• Rose bengal or lissamine green staining – outlines damaged cells at the limbal junction, useful for detecting early changes.

Laboratory investigations

• Polymerase chain reaction (PCR) of corneal scrapings – highly sensitive for HSV‑1 DNA; specificity >95 %.
• Viral culture – less commonly used due to slower turnaround.
• Serology – not routinely required but can support a diagnosis of recent HSV infection.
• Confocal microscopy – may visualize viral particles or inflammatory cells in research settings.

Differential diagnosis

Conditions that can mimic junctureal keratitis include: bacterial conjunctivitis, allergic keratoconjunctivitis, peripheral ulcerative keratitis, and early-stage corneal ulcer. Distinguishing features (e.g., presence of a dendritic pattern, response to antivirals) guide appropriate treatment.

Treatment Options

Treatment is tailored to the underlying cause, severity, and whether the disease is acute or recurrent.

Antiviral therapy (for HSV‑related cases)

• Topical trifluridine 1 % – applied five times daily for 7–10 days; effective for epithelial disease.
• Topical acyclovir 3 % ophthalmic ointment – applied five times daily; less irritating than trifluridine.
• Oral antivirals – valacyclovir 1 g twice daily or acyclovir 400 mg five times daily for 7–10 days are recommended for extensive disease or when rapid systemic control is needed.

Topical corticosteroids

Used with caution and only after antiviral coverage has been established, to reduce stromal inflammation and prevent scarring. Typical regimens start with prednisolone acetate 1 % drops 4×/day, tapering over 2–4 weeks.

Antibacterial agents

If secondary bacterial infection is suspected, broad‑spectrum fluoroquinolone drops (e.g., moxifloxacin 0.5 %) are prescribed.

Adjunctive therapies

• Lubricating eye drops – preservative‑free artificial tears q.i.d. to promote epithelial healing.
• Punctal plugs – for patients with dry eye contributing to poor healing.
• Topical anti‑inflammatory agents – cyclosporine 0.05 % for chronic ocular surface inflammation.

Procedural interventions

• Debridement – gentle mechanical removal of necrotic epithelium under slit‑lamp guidance can enhance drug penetration.
• Amniotic membrane transplantation – reserved for refractory cases with stromal thinning.
• Phototherapeutic keratectomy (PTK) – laser removal of superficial scar tissue in chronic disease.

Lifestyle and preventive measures during treatment

• Strict hand hygiene; avoid touching the eyes.
• Discontinue contact‑lens wear until the epithelium fully heals.
• Use a clean pillowcase and wash towels daily.

Living with Junctureal Keratitis

Even after the acute episode resolves, many patients experience recurrent episodes or lingering discomfort. Below are practical strategies to maintain ocular health.

Daily eye‑care routine

• Apply preservative‑free artificial tears at least four times a day.
• Follow a scheduled regimen for any prophylactic antiviral (e.g., valacyclovir 500 mg daily for frequent recurrences).
• Use a humidifier in dry indoor environments.
• Protect eyes from wind, dust, and smoke with wrap‑around sunglasses.

Monitoring and follow‑up

• Schedule ophthalmology visits every 3–6 months if you have a history of recurrent disease.
• Keep a symptom diary: note triggers (stress, UV exposure, fever) that precede flare‑ups.
• Promptly report new pain, sudden vision loss, or increased redness to your eye doctor.

Psychosocial aspects

Recurrent eye infections can cause anxiety and affect quality of life. Consider joining support groups (e.g., Herpes Eye Disease Support) and discuss coping strategies with your healthcare provider.

Prevention

While it may not be possible to eliminate all risk, the following evidence‑based measures markedly reduce the chance of developing or recurring junctureal keratitis.

• Vaccination – shingles vaccine (Shingrix) for adults >50 years reduces varicella‑zoster ocular involvement.
• Stress management – chronic stress is a known trigger for HSV reactivation; mindfulness, regular exercise, and adequate sleep are beneficial.
• UV protection – wear sunglasses with 100 % UVA/UVB blocking lenses; consider a wide‑brim hat.
• Contact‑lens hygiene – replace lenses as recommended, use appropriate disinfecting solutions, and never sleep in lenses unless approved.
• Dry‑eye control – treat underlying meibomian gland dysfunction, use omega‑3 supplements, and consider punctual plugs if needed.
• Prompt treatment of systemic viral illnesses – fever or cold sores should be managed early with antivirals to reduce ocular spread.

Complications

If left untreated or inadequately managed, junctureal keratitis can progress to more serious ocular pathology:

• Corneal scarring – leads to permanent visual acuity reduction.
• Neovascularization – new blood vessels may compromise corneal transparency.
• Stromal ulceration – deeper infection can precipitate perforation, a vision‑threatening emergency.
• Secondary bacterial keratitis – damaged epithelium predisposes to bacterial superinfection.
• Glaucoma – inflammation and steroid use can raise intra‑ocular pressure.
• Chronic dry eye syndrome – persistent surface irritation.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Herpes Simplex Keratitis.” Updated 2023. https://www.mayoclinic.org
2. American Academy of Ophthalmology. “Herpes Simplex Virus Keratitis Clinical Guidelines,” 2022.
3. World Health Organization. “Global Burden of Herpes Simplex Virus.” 2021. https://www.who.int
4. Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) Vaccine Recommendations.” 2022. https://www.cdc.gov
5. Cleveland Clinic. “Contact Lens‑Related Infections.” 2024. https://my.clevelandclinic.org
6. National Eye Institute (NEI). “Keratitis.” 2023. https://www.nei.nih.gov

```